A Keith Stewart

4PUBLICATIONS
60CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Mar 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz

|Jun 09, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur

|Oct 02, 2023
A Landmark Paper That Introduced Proteasome Inhibition in Myeloma.

Anup Joseph Devasia, Guido Lancman, A Keith Stewart

|Jun 06, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

Thomas Martin, Saad Z Usmani, Jesus G Berdeja

Pageof 1